WHO warns of the rise of gonorrhea resistance around the world

lack of new antibiotics to treat gonorrhea is partly due to a shortage of funds.
the 1920s, before the first drug to treat gonorrhea was discovered, the sexually transmitted disease had become almost incurable. More than 60 percent of the world's countries have reported cases of gonorrhea that can withstand the last antibiotic, according to a July 6 bulletin from the World Health Organization .WHO. The announcement also includes information on a new drug under development to treat gonorrhea.
since the 1930s, several classes of antibiotics have been used to eliminate the bacteria that cause gonorrhea, gonorrhea. However, the widespread use and misuse of these drugs has led to an increase in bacterial resistance strains.
"s best treatment for gonorrhea was in the 1980s, because there were so many drugs available for treatment. Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics and Policy in Washington, D.C., said. 'It's getting more and more different, ' he said.
recent years, health agencies in the United States, Europe and Canada have identified drug-resistant gonorrhoe bacteria as an emerging threat. If left untreated, gonorrhea increases a woman's risk of HIV infection, infertility or an alien pregnancy. Gonorrhea topped the list when the WHO teamed up with the Drug Initiative for Neglected Diseases (DNDi, a Geneva, Switzerland-based non-governmental organization) in May 2016 to combat antimicrobial resistance.
according to a July 7 paper published in the journal Public Library of Science-Medicine,
, antibiotics, the three common prescription drugs used to treat gonorrhea, suffer from strong resistance. Of the countries surveyed, 97 per cent reported resistance to cycloproxacin, one of the cheapest and most widely used treatments, while 81 per cent of gonorrhea cases reported resistance to azithromycin and 66 per cent were resistant to cephalosporine.
the search for new treatments, DNDi is "looking for drugs that are struggling to develop because of a lack of commercial viability," said Manica Balasegaram, head of the Antimicrobial Partnership. Balasegaram says policymakers are realizing that antibiotics should be used with caution, which is not a good thing for drugmakers' bottom lines.
have previously noted that the first drug in the new class of antibiotics, zoliflodacin, has been slow in the approval process. Entasis Therapeutics, a biotech company based in Waltham, Massachusetts, is developing the drug, which relies on public funding from the National Institutes of Health for the second phase of clinical trials in Zoliflodacin in 2015. Although the results showed that most gonorrhea patients treated had been cured, Balasegaram noted that the lack of investment hampered further development of the drug.
, DNDi and Entasis Therapeutics have announced that they will conduct phase III clinical trials in Zoliflodacin in about 650 gonorrhea patients in countries such as South Africa, the United States and Thailand. The team is expected to begin work in November 2018.
if Zoliflodacin is approved by regulators, Entasis Therapeutics will allow generic drug makers to sell the drug in most low- and middle-income countries. At the same time, the company will retain the exclusive nature of treatment in high-income countries. DNDi, on the other hand, says it will fund public health research to find the best way to ensure that drugs are not overused.
, however, the study itself does not satisfy Laxminarayan. He hopes the agencies will be able to provide rapid diagnosis while introducing new antibiotics, ensuring that people can only use new treatments if they are resistant to existing alternative therapies for gonorrhea. DNDi says it has been looking for such a simple diagnostic tool, but has not yet found it.
yes, we need a new drug. Laxminarayan said, "But without a quick diagnostic test, the drug would have the same fate as other drugs." "
gonorrhea is a sexually transmitted disease caused by gonorrhea Nesseria, which is mainly manifested in urinary systemic pus infections. Gonorrhoeth is Gloran-negative biculcobacteria, leaving the human body is not easy to survive, the general disinfectant is easy to kill it. Gonorrhea occurs mostly in sexually active young men and women. In recent years, there has been a marked increase in gonorrhea in the world.